Stocks losers - Yahoo Finance
- RR.LFinancial Times•6 hours ago
In 2009, Rolls-Royce paid £3.32m to rent a Dubai warehouse for eight months to store defence products destined for the Indian market. The only problem was that, apart from a test run, no Rolls-Royce stock ...
- SHP.LZacks•12 hours ago
Shire plc (SHPG) announced that the FDA has acknowledged receipt of the Class 2 resubmission of a New Drug Application (NDA) for pipeline candidate, SHP465.
- AZN.LReuters•13 hours ago
Bristol-Myers Squibb Co (BMY.N) shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co Inc's (MRK.N) leading position in the burgeoning immuno-oncolgy field. Lung cancer is by far the biggest oncology market and a handful of companies have been battling to become dominant in initial, or first-line, treatment, and to provide much-needed combination therapies. Merck shares rose 3.6 percent to $62.53, while Bristol fell to $49.23.